| 跌3091 | 涨2149 | | --- | --- | | 成交额6181亿 | 预测成交额1.92万亿,缩1270亿 | 12月9日开盘，A股市场震荡拉升，创业板指涨逾1%，沪指跌0.03%，深成指涨0.35%。 | 上证指数 | 深证成指 | 北证50 | | --- | --- | --- | | 3922.79 | 13376.53 | 1418.57 | | -1.28 -0.03% | +46.54 +0.35% | -7.68 -0.54% | | 科创50 | 创业板指 | 万得全A | | 1353.91 | 3224.50 | 6322.00 | | +3.12 +0.23% | +34.23 +1.07% | +6.53 +0.10% | | 沪深300 | 中证500 | 中证A500 | | 4624.80 | 7179.66 | 5564.18 | | +3.05 +0.07% | +7.29 +0.10% | +2.81 +0.05% | | 中证1000 | 深证100 | 中证红利 | | 7437.69 | 5895.60 | 5502.05 | | +14.65 ...

板块上来看，创新药概念股表现活跃，CPO、电子元器件、互联网等板块涨幅居前；而贵金属、海南自贸港、房地产等震荡调整。 一起来看下最新的市场情况及资讯。 12月9日开盘，A股市场震荡拉升，创业板指涨逾1%，沪指跌0.03%，深成指涨0.35%。 | 上证指数 | 深证成指 | 北证50 | | --- | --- | --- | | 3922.79 | 13376.53 | 1418.57 | | -1.28 -0.03% | +46.54 +0.35% | -7.68 -0.54% | | 科创50 | 创业板指 | 万得全A | | 1353.91 | 3224.50 | 6322.00 | | +3.12 +0.23% | +34.23 +1.07% | +6.53 +0.10% | | 沪深300 | 中证500 | 中证A500 | | 4624.80 | 7179.66 | 5564.18 | | +3.05 +0.07% | +7.29 +0.10% | +2.81 +0.05% | | 中证1000 | 深证100 | 中证红利 | | 7437.69 | 5895.60 | 5502.05 | ...

Group 1 - The Hang Seng Index fell by 0.84%, down 215 points, closing at 25,549 points, while the Hang Seng Tech Index dropped by 1.32%. The early trading volume in Hong Kong stocks reached HKD 1,078 million [1] - Optical communication stocks surged again, driven by the demand for high-speed optical transceiver modules due to AIDC development. Institutions expect a significant increase in shipment volume next year. Notable stock performances include: Hongteng Precision up 7.95%, Changfei Optical Fiber up 4.57%, Cambridge Technology up 3.06%, and Huiju Technology up 0.53% [1] - Zhuoyue Ruixin's stock rose over 16% on its second day of listing, with a total increase of 120% from the IPO price, approaching a market capitalization of HKD 10 billion. The company provides digital solutions for higher education institutions [1] Group 2 - Baiaosaitu-B's stock increased by over 8%, reaching a new high, as the company prepares to enter the A-share Sci-Tech Innovation Board [2] - Zhaoyan New Drug's stock rose by over 8% due to a recent surge in the price of experimental monkeys, with institutions indicating a potential widening supply-demand gap [3] - Oil stocks collectively declined, with weakened support for oil prices from geopolitical events. However, institutions remain optimistic about the long-term investment value of the three major oil companies. PetroChina fell by 3%, Sinopec by 2.21%, and CNOOC by 2.32% [3] - Non-ferrous metal stocks experienced significant declines, as the market focuses on the future interest rate policies of various central banks. Jiangxi Copper fell by 5.96%, Luoyang Molybdenum by 6.27%, and China Aluminum by 5.34% [3] Group 3 - Yino Pharmaceutical-B's stock fell by over 14%, with a cumulative decline of 25% since entering the market [4] - Ocean Park Hong Kong's stock dropped by 9%, hitting a new low for the year, as the controlling shareholder faces issues with financial product repayments [5]

Group 1 - The Hang Seng Index fell by 0.84%, down 215 points, closing at 25,549 points, while the Hang Seng Tech Index dropped by 1.32% [1] - The trading volume in the Hong Kong stock market reached HKD 107.8 billion in the morning session [1] - Optical communication stocks surged, driven by increased demand for high-speed optical transceiver modules, with institutions predicting a significant rise in shipment volumes next year [1] Group 2 - Notable gainers included Hongteng Precision, which rose by 7.95%, and Changfei Optical Fiber, which increased by 4.57% [1] - Zhaoyan New Drug saw an increase of over 8% due to a surge in the price of experimental monkeys, with institutions indicating a potential widening supply-demand gap [1] - The stock of Excellence Education, a provider of digital solutions for higher education, rose over 16% on its second day of trading, with its market value approaching HKD 10 billion [1] Group 3 - Oil stocks collectively declined, with geopolitical events weakening support for oil prices, although institutions remain optimistic about the long-term investment value of major oil companies [1] - PetroChina fell by 3%, Sinopec by 2.21%, and CNOOC by 2.32% [1] Group 4 - The non-ferrous metals sector faced significant declines, with Jiangxi Copper down 5.96%, Luoyang Molybdenum down 6.27%, and China Aluminum down 5.34% due to market concerns over central banks' interest rate policies [2] - Silver Noble Pharmaceuticals saw a drop of over 14%, with a cumulative decline of 25% since entering the market [2] Group 5 - Ocean Park Corporation's stock fell by 9%, reaching a new low for the year, amid financial product repayment issues faced by its controlling shareholder [3]

Group 1 - Bai'ao Saitou-B (02315) rose over 9.4% after announcing its RMB ordinary shares will be listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 10, 2025 [1] - "First Chinese Noodle Restaurant Stock" Yujian Xiaomian (02408) increased by 4.69% as the chairman announced plans to open its first store in Singapore by the end of the month, marking a step towards internationalization [1] - Chinese property stocks collectively declined, with China Overseas Hong Kong Group (00081) down 9.38%, Greentown China (03900) down 4.66%, New World Development (01030) down 3.24%, and Sunac China (01918) down 1.55% [1] Group 2 - Haichang Ocean Park (02255) fell by 9% amid ongoing issues related to the "Xiangyuan System" where several income rights products have not been redeemed [1] - Non-ferrous metal stocks saw significant declines, with Jiangxi Copper (00358) down 6.24%, Luoyang Molybdenum (03993) down 6.48%, China Aluminum (02600) down 5.43%, and Zijin Mining (02899) down 4.24% due to expectations of interest rate adjustments by the Bank of Japan and hawkish comments from European Central Bank officials [2] - Kangnai Optical (02276) dropped over 1.32% as Google announced it is developing two types of AI glasses to compete with Meta's products [2] Group 3 - Zhaoyan New Drug (06127) surged over 7.76% as reports indicated that the price of crab-eating monkeys has exceeded 100,000 yuan [2] - Kingsoft Cloud (03896) rose over 1.78% following a Goldman Sachs report highlighting Xiaomi's exploration of large language models for various applications [2] - Cornerstone Pharmaceuticals-B (02616) increased by over 0.5% after announcing that its drug has been included in the latest National Medical Insurance Drug List, effective January 1, 2026 [3] Group 4 - Marvell Technology (MRVL.US) fell 6.99% as reports indicated Microsoft is negotiating with Broadcom for future custom chip designs, potentially shifting away from Marvell [4] - GCL Global (GCL.US) rose 1.74% after announcing a $3 million strategic investment from ADATA [4] - Kymera Therapeutics (KYMR.US) surged 41.55% to a record high following positive trial results for its drug KT-621 [4] Group 5 - Wave Life Sciences (WVE.US) skyrocketed 147.26% to a yearly high after reporting positive mid-term results for its obesity treatment WVE-007 [5] - Warner Bros. Discovery (WBD.US) rose 4.41% amid speculation that Paramount is considering a higher acquisition offer for the company [5] - Carvana (CVNA.US) increased by 12.06% after being announced for inclusion in the S&P 500 index, effective December 22 [5]

港股方面，三大指数悉数下跌，百度集团、华虹半导体、哔哩哔哩跌幅居前。 | 恒生指数 | 恒生国企 | | 恒生科技 | | | --- | --- | --- | --- | --- | | 25684.64 | 9035.91 | | 5628.08 | | | -80.72 -0.31% | -47.62 -0.52% | | -34.47 -0.61% | | | 恒指期货 | 港股通50 | | 恒生生物科技 | | | 25727 | 3868.99 | | 0.00 | | | -50 -0.19% | -1.96 | -0.05% | 0.00 | 0.00% | 【导读】创新药概念股表现活跃，CPO板块走高 一起来看下最新的市场情况及资讯。 12月9日开盘，A股市场震荡拉升，创业板指涨逾1%，沪指跌0.03%，深成指涨0.35%。 板块上来看，创新药概念股表现活跃，CPO、电子元器件、互联网等板块涨幅居前；而贵金属、海南自贸港、房地产等震荡调整。 | 名称 | 现价 | 涨跌幅 = | 总市值 三 | | --- | --- | --- | --- | | 百度集团-SW | 122.000 ...

Core Viewpoint - The stock price of Zhaoyan New Drug (06127) has increased significantly, driven by a surge in the price of experimental monkeys, particularly the crab-eating macaque, which has seen a supply shortage and price increase [5]. Group 1: Company Performance - Zhaoyan New Drug's stock price rose by 7.33% to HKD 17.43, with a trading volume of HKD 211 million [5]. - The company is expected to benefit from the rising prices of experimental monkeys due to its acquisition of monkey breeding facilities, which aims to create an integrated industry chain [5]. Group 2: Industry Trends - The price of crab-eating macaques has surpassed HKD 100,000, with reports indicating prices have reached HKD 120,000 to HKD 130,000 due to supply shortages [5]. - Demand for experimental monkeys is projected to be between 51,300 to 62,600 annually from 2025 to 2027, while supply is estimated at 49,000 to 52,400, indicating a potential supply-demand gap [5]. - The resurgence in new drug development is expected to drive up the usage of experimental monkeys, exacerbating the supply constraints in the short term [5].

Group 1 - The stock of Zhaoyan New Drug (06127.HK) experienced a significant increase, rising over 10% at one point and currently up by 9.61%, trading at 17.8 HKD [1] - The trading volume reached 172 million HKD [1]

Group 1 - The CRO index experienced a 2% increase during intraday trading, indicating a broad upward trend among constituent stocks [1] - Notable performers included Zhaoyan New Drug, which rose over 9%, and Chengdu Xian Dao, which increased by 6.25% [1] - Other stocks such as Meidi Xi, Yinuosi, and Yaoshi Technology also saw gains, contributing to the overall positive performance of the sector [1]

Group 1 - The core viewpoint of the article highlights a significant increase in the price of experimental monkeys, particularly the crab-eating macaques, which have surpassed 100,000 yuan, with reports indicating prices have risen to 120,000-130,000 yuan due to supply shortages [1] - The trading performance of Zhaoyan New Drug (603127) shows a rise of over 10%, currently at 17.8 HKD with a trading volume of 172 million HKD, indicating positive market sentiment [1] - According to estimates from Founder Securities, the supply of experimental monkeys is projected to be around 49,000-52,400 annually from 2025 to 2027, while demand is expected to be between 51,300-62,600, suggesting a widening supply-demand gap due to increased usage in new drug development [1] Group 2 - The report from招商证券 indicates that Zhaoyan New Drug's acquisition of monkey breeding facilities aims to create an integrated industry chain, positioning the company to benefit from the rising prices of experimental monkeys, which could enhance profit margins [1] - The short-term outlook suggests that the demand for experimental monkeys is driven by a resurgence in new drug research, while improvements in supply are expected to be challenging, potentially leading to a sustained supply-demand imbalance [1]